(Translated by https://www.hiragana.jp/)
Drugs.com - Prescription Drug Information Skip to main content

Find Drugs & Conditions

Drugs.com is the most popular, comprehensive and up-to-date source of drug information online. Providing free, peer-reviewed, accurate and independent data on more than 24,000 prescription drugs, over-the-counter medicines & natural products.

Travere Therapeutics Announces Full FDA Approval of Filspari (sparsentan), the Only Non-Immunosuppressive Treatment that Significantly Slows Kidney Function Decline in IgA Nephropathy

Travere Therapeutics, Inc., (Nasdaq: TVTX) today announced that the U.S. Food and Drug Administration (FDA) has granted full approval to Filspari®...

2007 to 2023 Saw Decline in Menopausal Hormone Therapy Usage Rates

Menopausal hormone therapy (HT) usage rates declined from 2007 to 2023 and remain low, according to a study presented at the annual meeting of The Menopause...

Omitting 5-FU Bolus Does Not Reduce Survival in Advanced Cancer

Omission of 5-fluorouracil (5-FU) from the first-line FOLFOX, FOLFIRI, and FOLFIRINOX regimens is not associated with reduced survival among patients with...

Weight-Loss Surgery Benefits Blood Pressure Management

Bariatric surgery emerges as a durable solution for obesity-related hypertension, according to a study presented at the American Heart Association Hypertension...

Depemokimab Cuts Exacerbation Rate in Eosinophilic Asthma

For patients with severe asthma with an eosinophilic phenotype, depemokimab reduces the annualized rate of exacerbations, according to a study published...

U.S. Suicide Rates Rise in Less Affluent Areas

An analysis of where suicides are occurring in the United States shows that, tragically, location matters. People living in poorer areas with fewer resources...

Once-weekly dose of insulin efsitora alfa delivers A1C reduction consistent with the most advanced daily insulin in people with type 2 diabetes

INDIANAPOLIS, Sept. 10, 2024. Eli Lilly and Company today announced detailed results from the QWINT-2 phase 3 trial evaluating once-weekly insulin efsitora...

Asthma Could Raise Miscarriage, Infertility Risks for Women: Study

Having asthma appears linked to raised odds for miscarriage and troubles with fertility among women, new Danish research shows. “We found that women...

Pandemic Isolation May Have Caused Rapid Brain Aging in Teen Girls

New research uncovers a possible reason why teenaged girls struggled so mightily with their mental health during the pandemic: Scans showed their brains...

Could Sulthiame, a Pill Approved in Europe for Epilepsy, Help Ease Sleep Apnea?

A European epilepsy drug could be an effective treatment for sleep apnea, a new study suggests. Patients who took sulthiame had few pauses in their breathing...

First Patients Treated in Phase 2 Clinical Trial of STAT3 Inhibitor in Combination with Radiation for the Treatment of Glioblastoma

HOUSTON, Sept. 9, 2024. Moleculin Biotech, Inc., ("Moleculin" or the "Company), a Phase 3 clinical-stage pharmaceutical company with a broad portfolio...

FDA Warns Consumers Not to Purchase or Use Umary and Amazy Products As They May Be Harmful To Your Health

FDA is warning consumers not to purchase or use Umary and Amazy products, marketed as dietary supplements, as they may be harmful to your health. This...

3-in-1 Blood Pressure Pill Could Be Treatment Advance

An experimental three-in-one blood pressure pill works better than layering on meds one at a time, a new clinical trial shows. After a month on the combo...

Read more news...

Recently Added

Recently added consumer and prescribing information: Pavblu, Livdelzi, Yorvipath, Crexont, Lymphir, Epysqli, Pyzchiva, Ahzantive, Ohtuvayre, Sofdra

For Consumers

For Professionals

For Researchers

Latest FDA New Drug Approvals

  • Pavblu Pavblu (aflibercept-ayyh) is a vascular endothelial growth factor (VEGF) inhibitor biosimilar to Eylea indicated for the treatment of...
  • Lazcluze Lazcluze (lazertinib) is a kinase inhibitor used in combination with amivantamab for the treatment of certain patients with epidermal...
  • Niktimvo Niktimvo (axatilimab-csfr) is a colony stimulating factor-1 receptor (CSF-1R)-blocking antibody used for the treatment of chronic...

More FDA approvals

Drugs in Development (Not yet approved)

  • Yutrepia Yutrepia (treprostinil) is an inhaled dry powder formulation of treprostinil tentatively approved for the treatment of pulmonary arterial...

More drugs in development